Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Asian markets in the red again
Thu, 7 Aug 09:30 am

All major Asian stock markets have opened the day in the red with stock markets in China (down 0.6%) and Hong Kong (down 0.5 %) leading the pack of losers. The Indian share markets have also opened the day on a negative note. The sectoral indices are trading mixed with the information technology index leading the losses. However, the capital goods index is trading firm.

The Sensex today is down by around 26 points (0.1%), while the NSE-Nifty is down by about 6 points (0.1%). However, mid and small cap stocks are trading in the green with the BSE Mid Cap and BSE Small Cap indices up by around 0.3% and 0.4% respectively. The rupee is currently trading at Rs 61.29 to the US dollar.

Public Sector Bank stocks have opened the day on a mixed note with Union Bank of India and Allahabad Bank leading the gains. However, IDBI Bank and Indian Overseas Bank are trading weak. Public sector lender IDBI Bank has announced its results for the quarter ended June 2014. During the quarter, the bank reported flat growth at the topline level with interest earned standing at Rs 67,329.8 m. Other income declined by 30.3% YoY to Rs 4,997.5 m. Owing to higher interest expended, operating income before provisions and contingencies dropped by 29.5% YoY to Rs 9,282.6 m. At the bottomline level, net profit plunged by 65.4% YoY to Rs 1,061.7 m. Net profit margin contracted from 4.6% in 1QFY14 to 1.6% in 1QFY15.

Indian Pharma stocks have mainly opened the day on a firm note with Indoco Remedies and Glenmark Pharma leading the gains. As per the financial daily, Mumbai-based pharma major Lupin has signed a marketing pact with South Korea's LG Life Sciences to launch its anti-diabetes drug in India. According to the agreement, Lupin will launch and will be responsible for the marketing and sales of LG Life Sciences' Insulin Glargine, a novel insulin analogue, under the brand name BasugineTM. It must be noted that Insulin Glargine is indicated for the treatment of adult patients with type 1 diabetes mellitus or in type 2 diabetes mellitus. This deal will help Lupin further strengthen its diabetes portfolio. As per IMS MAT data reported in the daily, the overall diabetes market size within the Indian pharmaceutical Market (IPM) stands at Rs 60.32 bn and is growing at 18% year-on-year.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary


What else is happening in the markets today? Dig in...

Equitymaster requests your view! Post a comment on "Asian markets in the red again". Click here!

  

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project (Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE BANKEX


Mar 3, 2021 (Close)

S&P BSE BANKEX 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS